GO:0004119 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004119 describes a phosphodiesterase catalytic activity that hydrolyzes nucleoside 3',5'-cyclic phosphates to nucleoside 5'-phosphates and is inhibited by cGMP.
• This activity is a molecular_function annotation, not a specific gene product; it is carried by members of the cyclic nucleotide phosphodiesterase (PDE) superfamily, particularly PDE3-type enzymes.
• cGMP inhibition is a defining regulatory feature: elevated cGMP reduces the rate of cAMP hydrolysis by these enzymes, linking cGMP and cAMP signaling pathways.
• PDE3B is a well-characterized enzyme with cGMP-inhibited cyclic nucleotide phosphodiesterase activity and can hydrolyze cUMP as well as cAMP.
• Dysregulation of cGMP-inhibited PDE activity is implicated in cardiovascular disease, metabolic disorders, and cancer, making it a major drug target.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect the causal roles of PDE genes in disease and to validate drug targets.
Description
GO:0004119, 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity, is a molecular function term in the Gene Ontology that describes the catalysis of the reaction nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate, with catalytic activity decreased in the presence of cGMP. This activity is a cornerstone of cyclic nucleotide signaling because it terminates the action of cAMP and cGMP, two second messengers that control diverse physiological processes including cardiac contractility, vascular tone, platelet aggregation, and metabolism. The cGMP-inhibited subclass is unique because cGMP acts as a competitive inhibitor, allowing crosstalk between the cGMP and cAMP pathways. Researchers study this activity to understand how cells integrate cyclic nucleotide signals and to develop therapeutics for cardiovascular and metabolic diseases. The enzyme activity is encoded by a subset of phosphodiesterase genes, notably PDE3A and PDE3B, which are the principal cGMP-inhibited PDEs in humans. Beyond cAMP, PDE3B can also hydrolyze cUMP, expanding the range of cyclic nucleotides regulated by this activity. Because the term is defined by its catalytic behavior and inhibition profile, it is essential to distinguish it from other PDE activities such as cGMP-specific or cAMP-specific phosphodiesterases.
3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity At A Glance
| GO ID | GO:0004119 |
|---|---|
| GO term | 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | (none) |
| Major function | Catalysis of nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate; activity is decreased by cGMP |
| Reaction direction | Hydrolytic cleavage of the cyclic phosphodiester bond |
| Inhibitor | cGMP acts as a competitive inhibitor of catalysis |
| Representative enzymes | PDE3A and PDE3B are classical cGMP-inhibited phosphodiesterases |
| Substrate range | cAMP is a primary substrate; cUMP can also be hydrolyzed by PDE3B |
What Is GO:0004119?
In our own words, GO:0004119 refers to an enzymatic activity that breaks the 3',5'-cyclic phosphodiester bond of a nucleoside cyclic phosphate, producing the corresponding nucleoside 5'-phosphate, and whose catalytic rate is reduced when cGMP is present. The reaction is hydrolytic and requires water. The defining feature is not the substrate alone but the sensitivity to cGMP inhibition, which distinguishes it from other cyclic nucleotide phosphodiesterases.
Why Is 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity Important in Cell Biology?
This activity is important because it provides a direct molecular link between cGMP and cAMP signaling, two pathways that often have opposing effects in cells. By hydrolyzing cAMP and being inhibited by cGMP, enzymes with this activity act as signal integrators that shape the amplitude and duration of cyclic nucleotide responses. Pharmacological inhibition of these enzymes is clinically validated for cardiovascular indications, and ongoing research explores their roles in metabolic disease and cancer. Therefore, understanding GO:0004119 at the molecular, cellular, and organismal levels is critical for both basic biology and drug discovery.
• Controls cAMP levels in cardiac myocytes, vascular smooth muscle, and platelets, influencing contractility and thrombosis.
• Mediates cGMP-dependent inhibition of cAMP hydrolysis, a key crosstalk node between two second messenger systems.
• Represents the molecular target of PDE3 inhibitors used in heart failure and intermittent claudication.
• Contributes to metabolic regulation, including insulin secretion and lipid metabolism, through PDE3B.
• Can hydrolyze cUMP, suggesting broader roles in pyrimidine cyclic nucleotide signaling.
• Dysregulation is associated with cancer cell proliferation and survival, making it a potential oncology target.
• Provides a paradigm for understanding how enzyme inhibition by a product analog shapes signaling dynamics.
• Enables researchers to study compartmentalized cyclic nucleotide signaling using selective inhibitors and genetic models.
What Happens During 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity?
Substrate binding and cyclic phosphate recognition
In simple terms: The enzyme grabs a cyclic nucleotide like cAMP and positions it for cleavage.
Enzymes with GO:0004119 activity bind nucleoside 3',5'-cyclic phosphates, such as cAMP, in a catalytic pocket that recognizes the cyclic phosphate moiety and the purine ring. The binding is non-covalent and reversible, allowing turnover. The active site contains conserved histidine and aspartate residues that coordinate a metal ion, typically a divalent cation, which is required for catalysis.
Hydrolytic cleavage of the 3',5'-cyclic phosphodiester bond
In simple terms: Water is used to break the ring, turning cAMP into AMP.
The catalytic mechanism involves nucleophilic attack by a water molecule, activated by the metal ion, on the phosphorus atom of the cyclic phosphate. This hydrolyzes the 3',5'-cyclic phosphodiester bond, yielding the corresponding nucleoside 5'-phosphate (e.g., AMP from cAMP). The reaction is exergonic and essentially irreversible under physiological conditions.
cGMP binding and inhibition
In simple terms: cGMP fits into the same pocket but is not cleaved efficiently, so it blocks cAMP from being broken down.
cGMP competes with cAMP for binding to the catalytic site. When cGMP occupies the site, the hydrolysis of cAMP is decreased, defining the cGMP-inhibited property of this activity. This inhibition is a key regulatory mechanism that allows cGMP to elevate cAMP levels indirectly. The inhibition is not necessarily complete; it depends on relative concentrations and enzyme isoform.
Product release and catalytic cycle
In simple terms: After the reaction, the product leaves and the enzyme is ready to work again.
Following hydrolysis, the nucleoside 5'-phosphate product is released, and the enzyme returns to its resting state. The catalytic cycle can be repeated many times per second, depending on the enzyme and conditions. Product release may be rate-limiting for some isoforms. The overall rate is modulated by cGMP concentration and other cellular factors.
Substrate specificity and alternative substrates
In simple terms: Some versions of this enzyme can also break down other cyclic nucleotides like cUMP.
While cAMP is the canonical substrate, PDE3B can hydrolyze cUMP, a pyrimidine cyclic nucleotide, with lower efficiency. This broadens the potential signaling impact of GO:0004119. The specificity is determined by active site residues and isoform-specific domains.
Key Genes Involved in GO:0004119 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity
The following genes encode proteins that exhibit or are directly associated with 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity, based on published biochemical and pharmacological evidence.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE3A | cGMP-inhibited cAMP phosphodiesterase; major cardiac and platelet isoform | Target for heart failure and cardiovascular drugs; studied in contractility and thrombosis |
| PDE3B | cGMP-inhibited cAMP phosphodiesterase; also hydrolyzes cUMP | Key regulator of insulin secretion and lipid metabolism; metabolic disease research |
| PDE1A | Calmodulin-dependent PDE; can be regulated by cGMP | Less direct cGMP inhibition; studied in vascular and neuronal signaling |
| PDE1B | Calmodulin-dependent PDE | Neuronal signaling and potential neuropsychiatric relevance |
| PDE1C | Calmodulin-dependent PDE | Vascular smooth muscle and proliferation research |
| PDE2A | cGMP-stimulated PDE | Contrasts with cGMP-inhibited activity; important for cGMP/cAMP crosstalk |
| PDE4A | cAMP-specific PDE | Inflammatory and CNS research; not cGMP-inhibited |
| PDE4B | cAMP-specific PDE | Inflammation and memory research |
| PDE4D | cAMP-specific PDE | Cardiovascular and metabolic studies |
| PDE5A | cGMP-specific PDE | Erectile dysfunction and pulmonary hypertension target |
| PDE6 | Photoreceptor PDE | Vision research; cGMP-specific |
| PDE7A | cAMP-specific PDE | Immune and metabolic research |
| PDE7B | cAMP-specific PDE | Brain and metabolic studies |
| PDE8A | cAMP-specific PDE | Thyroid and metabolic research |
| PDE9A | cGMP-specific PDE | CNS and metabolic research |
| PDE10A | cAMP/cGMP dual-specific PDE | Striatal signaling and psychiatric research |
| PDE11A | cAMP/cGMP dual-specific PDE | Adrenal and reproductive research |
How Is 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity Regulated?
The activity of cGMP-inhibited cyclic nucleotide phosphodiesterases is regulated at multiple levels. Acute regulation occurs through cGMP binding, which directly inhibits catalysis. Phosphorylation by protein kinase A and protein kinase B can modulate PDE3 activity, altering its affinity for substrates or its sensitivity to cGMP. Subcellular localization, often mediated by N-terminal domains, determines access to distinct cyclic nucleotide pools. In addition, expression levels of PDE3A and PDE3B are regulated by hormones and metabolic status, affecting overall cellular capacity to hydrolyze cAMP.
3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE3A | Heart failure, hypertension, platelet aggregation | Cardiomyocyte-specific knockout; point mutation of catalytic residue |
| PDE3B | Insulin resistance, obesity, type 2 diabetes | Adipocyte or beta-cell knockout; overexpression in metabolic tissues |
| PDE3A/B | Cancer cell proliferation and survival | Xenograft models with CRISPR knockout or overexpression |
| PDE1A | Vascular dysfunction, neurodegeneration | Knockout in smooth muscle or neurons |
| PDE2A | Cognitive disorders, adrenal function | Conditional knockout in brain |
Cardiovascular disease
cGMP-inhibited PDE activity, primarily PDE3A, is a well-established drug target in heart failure and peripheral arterial disease. Inhibitors such as milrinone and cilostazol increase cAMP levels, enhancing cardiac contractility and vasodilation. Dysregulated PDE3 activity contributes to pathological remodeling and arrhythmias. Genetic variants in PDE3A have been linked to hypertension and platelet function.
Metabolic disorders
PDE3B is highly expressed in adipose tissue, liver, and pancreatic beta cells, where it regulates insulin secretion and lipid metabolism. Reduced PDE3B activity is associated with increased insulin sensitivity in some models, while excessive activity may contribute to insulin resistance. The ability of PDE3B to hydrolyze cUMP suggests additional roles in metabolic signaling.
Cancer
Cyclic nucleotide phosphodiesterases, including cGMP-inhibited isoforms, are implicated in cancer cell proliferation, survival, and migration. Elevated PDE3 expression has been observed in some tumors, and inhibition can reduce tumor growth in preclinical models. The cGMP-inhibited activity may modulate cGMP-mediated effects on angiogenesis and apoptosis.
From 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDE3A alter cardiac contractility? | PDE3A knockout mouse or human iPSC-derived cardiomyocytes |
| Does cGMP inhibition of PDE3B require a specific catalytic residue? | Point mutation of the catalytic histidine in PDE3B |
| Can a disease-associated PDE3A variant recapitulate the phenotype? | Knock-in of the variant allele in cell lines or mice |
| Where is PDE3B localized in adipocytes? | Tagged knock-in of PDE3B with fluorescent protein |
| Does overexpression of PDE3A increase cAMP hydrolysis? | Transient or stable overexpression in HEK293 or cardiomyocytes |
| Which genes interact with PDE3A in disease? | CRISPR library screening in relevant cell models |
How to Study the 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioenzymatic PDE assay | Hydrolysis of cyclic nucleotides | Determining enzyme kinetics and cGMP inhibition |
| ELISA for cAMP/cGMP | Intracellular cyclic nucleotide levels | Assessing PDE inhibitor effects in cells |
| FRET biosensors | Real-time cAMP/cGMP dynamics | Live-cell imaging of compartmentalized signaling |
| Western blot | Protein expression and phosphorylation | Validating knockout or overexpression |
| CRISPR knockout | Loss-of-function phenotype | Target validation in disease models |
| CRISPR point mutation | Specific amino acid function | Testing catalytic residues or regulatory sites |
| RNA-seq | Transcriptional changes | Pathway analysis after PDE manipulation |
| Proteomics | Protein interactions and modifications | Identifying PDE3 interactors |
Biochemical phosphodiesterase assays
Enzymatic activity of cGMP-inhibited PDEs is measured using radiolabeled cAMP or cGMP, followed by separation of cyclic nucleotides from 5'-monophosphates by chromatography or precipitation. These assays allow determination of Km, Vmax, and IC50 for cGMP inhibition. They are essential for confirming that a gene product has GO:0004119 activity.
Cyclic nucleotide quantification in cells
Cellular cAMP and cGMP levels can be measured by ELISA, mass spectrometry, or genetically encoded FRET sensors. These methods reveal how modulation of PDE activity affects second messenger pools in real time. They are often combined with PDE inhibitors to assess cGMP-inhibited activity specifically.
Genetic manipulation and phenotyping
CRISPR knockout, point mutation, and overexpression models enable causal testing of PDE genes. Phenotypes such as contractility, insulin secretion, or proliferation are quantified using standard assays. Rescue experiments with wild-type or mutant cDNA confirm specificity.
Structural and computational approaches
X-ray crystallography and cryo-EM provide atomic details of the catalytic site and cGMP binding. Molecular dynamics simulations can predict how mutations affect substrate binding and inhibition. These methods complement biochemical data to explain the molecular basis of cGMP inhibition.
How CRISPR Can Be Used to Study GO:0004119 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity
Knockout
CRISPR knockout of PDE3A or PDE3B eliminates the cGMP-inhibited cyclic nucleotide phosphodiesterase activity, allowing researchers to observe loss-of-function phenotypes such as increased cAMP levels, altered contractility, or metabolic changes. Knockout cell lines and animal models are essential for target validation.
Point Mutation
Point mutations can be introduced into the catalytic domain to abolish enzymatic activity or into the cGMP-binding site to alter inhibition. For example, mutating the catalytic histidine in PDE3B can distinguish substrate hydrolysis from cGMP binding. These models provide mechanistic insights beyond simple knockout.
Knock-in
Knock-in of disease-associated variants or tagged versions of PDE3A/B allows study of allele-specific effects and protein localization. Fluorescent or epitope tags enable imaging and proteomics without altering endogenous regulation.
Overexpression
Overexpression of wild-type or mutant PDE3A/B in cell lines increases cAMP hydrolysis and can mimic pathological states. This approach is useful for testing whether increased activity is sufficient to drive disease phenotypes.
How EDITGENE Supports 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity Research
Researchers studying 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling or disease phenotype. EDITGENE provides the CRISPR tools and services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity research.
Frequently Asked Questions About 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity
What is 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity?
It is a molecular function (GO:0004119) that hydrolyzes cyclic nucleotides like cAMP to their 5'-monophosphates, and the activity is inhibited by cGMP.
What genes are involved in 3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity?
The primary genes are PDE3A and PDE3B, which encode cGMP-inhibited phosphodiesterases.
How is this activity different from other phosphodiesterases?
Unlike cAMP-specific or cGMP-specific PDEs, this activity is defined by inhibition by cGMP, which competes with cAMP for the catalytic site.
What diseases are associated with cGMP-inhibited PDE activity?
Cardiovascular diseases such as heart failure, metabolic disorders like insulin resistance, and certain cancers have been linked to PDE3 activity.
Can PDE3B hydrolyze cUMP?
Yes, PDE3B has been shown to hydrolyze cUMP, expanding its substrate range beyond cAMP.
What are the substrates of this enzyme activity?
The canonical substrate is cAMP, but cGMP can bind and inhibit; cUMP is also a substrate for PDE3B.
How can I study cGMP-inhibited PDE activity in the lab?
Common methods include radioenzymatic assays, ELISA for cyclic nucleotides, and CRISPR knockout or overexpression models.
What is the role of cGMP in this activity?
cGMP acts as a competitive inhibitor, reducing the hydrolysis of cAMP and thereby modulating signaling crosstalk.
Are there drugs that target this activity?
Yes, PDE3 inhibitors such as milrinone and cilostazol are used clinically for cardiovascular indications.
How does CRISPR help in studying this activity?
CRISPR knockout, point mutation, knock-in, and overexpression allow causal testing of PDE genes in disease models.
Conclusion
GO:0004119 defines a crucial enzymatic activity that integrates cGMP and cAMP signaling through cGMP-inhibited hydrolysis of cyclic nucleotides. The principal enzymes PDE3A and PDE3B are validated drug targets and play key roles in cardiovascular and metabolic physiology. Understanding this activity requires a combination of biochemical, genetic, and structural approaches. CRISPR-based models from EDITGENE provide powerful tools to dissect the precise roles of these enzymes in health and disease.
References
- 1. Kelly MP et al.. 2025. Cyclic nucleotide phosphodiesterases as drug targets.. Pharmacol Rev 77(3):100042 PMID: 40081105
- 5. Appleman MM et al.. 1973. Cyclic nucleotide phosphodiesterases.. Adv Cyclic Nucleotide Res 3:65-98 PMID: 4361529
- 7. Ostermeyer J et al.. 2018. cUMP hydrolysis by PDE3B.. Naunyn Schmiedebergs Arch Pharmacol 391(9):891-905 PMID: 29808231
